OBJECTIVE: To investigate the prevalence of and evaluate screening modalities for undiagnosed tuberculosis (TB) in antiretroviral therapy (ART) eligible adults in South Africa. METHODS: Individuals were screened for TB using symptoms, chest radiograph (CXR) and two sputum specimens for microscopy and culture, and were then followed for <6 months to determine TB diagnoses. RESULTS: Among 361 participants (67% female, median age 38 years, median CD4 count 120 cells/mm(3)), 64 (18%) were sputum culture-positive; 114 (32%) fulfilled any TB case definition (culture- and/or smear-positive, or improvement on specific treatment). Symptom screening comprising any of cough, appetite loss or night sweats > 2 weeks had a sensitivity and specificity of respectively 74.5% and 50.8%. Sensitivity was increased by CXR (to 96.1%), but not by smear microscopy. The World Health Organization symptom screen had a sensitivity and specificity of respectively 96.1% and 5.2% in our study population; the addition of CXR increased sensitivity to 100%. Median time to TB treatment was 8 days for diagnoses based on CXR (n = 72) vs. 37 days for diagnoses based only on sputum culture (n = 14). CONCLUSIONS: The very high prevalence of undiagnosed TB among patients presenting for ART mandates their routine investigation. CXR improved sensitivity substantially, allowed rapid treatment initiation and should be routine, where available, pending better point-of-care diagnostics.
OBJECTIVE: To investigate the prevalence of and evaluate screening modalities for undiagnosed tuberculosis (TB) in antiretroviral therapy (ART) eligible adults in South Africa. METHODS: Individuals were screened for TB using symptoms, chest radiograph (CXR) and two sputum specimens for microscopy and culture, and were then followed for <6 months to determine TB diagnoses. RESULTS: Among 361 participants (67% female, median age 38 years, median CD4 count 120 cells/mm(3)), 64 (18%) were sputum culture-positive; 114 (32%) fulfilled any TB case definition (culture- and/or smear-positive, or improvement on specific treatment). Symptom screening comprising any of cough, appetite loss or night sweats > 2 weeks had a sensitivity and specificity of respectively 74.5% and 50.8%. Sensitivity was increased by CXR (to 96.1%), but not by smear microscopy. The World Health Organization symptom screen had a sensitivity and specificity of respectively 96.1% and 5.2% in our study population; the addition of CXR increased sensitivity to 100%. Median time to TB treatment was 8 days for diagnoses based on CXR (n = 72) vs. 37 days for diagnoses based only on sputum culture (n = 14). CONCLUSIONS: The very high prevalence of undiagnosed TB among patients presenting for ART mandates their routine investigation. CXR improved sensitivity substantially, allowed rapid treatment initiation and should be routine, where available, pending better point-of-care diagnostics.
Authors: Adrienne E Shapiro; Ting Hong; Sabina Govere; Hilary Thulare; Mahomed-Yunus Moosa; Afton Dorasamy; Carole L Wallis; Connie L Celum; Jacques Grosset; Paul K Drain Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Christina Yoon; Fred C Semitala; Lucy Asege; Jane Katende; Sandra Mwebe; Alfred O Andama; Elly Atuhumuza; Martha Nakaye; Derek T Armstrong; David W Dowdy; Charles E McCulloch; Moses Kamya; Adithya Cattamanchi Journal: Am J Respir Crit Care Med Date: 2019-03-01 Impact factor: 21.405
Authors: C Yoon; L H Chaisson; S M Patel; I E Allen; P K Drain; D Wilson; A Cattamanchi Journal: Int J Tuberc Lung Dis Date: 2017-09-01 Impact factor: 2.373
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Christopher J Hoffmann; James J Lewis; David W Dowdy; Katherine L Fielding; Alison D Grant; Neil A Martinson; Gavin J Churchyard; Richard E Chaisson Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Catriona J Waitt; Elizabeth C Joekes; Natasha Jesudason; Peter I Waitt; Patrick Goodson; Ganizani Likumbo; Samuel Kampondeni; E Brian Faragher; S Bertel Squire Journal: Eur Radiol Date: 2013-05-08 Impact factor: 5.315
Authors: Maria de Fátima Pessoa Militão Albuquerque; Isabella Coimbra; Joanna d'Arc Batista; Magda Maruza; Ricardo A A Ximenes; Heloísa R Lacerda; Demócrito B Miranda-Filho; Marcela L Santos; Laura C Rodrigues Journal: BMC Public Health Date: 2014-03-29 Impact factor: 3.295
Authors: Katherine L Fielding; Salome Charalambous; Christopher J Hoffmann; Suzanne Johnson; Mpho Tlali; Susan E Dorman; Anna Vassall; Gavin J Churchyard; Alison D Grant Journal: Trials Date: 2015-03-28 Impact factor: 2.279